JP7410852B2 - 結節性痒疹患者における皮膚病変およびそう痒の治療 - Google Patents

結節性痒疹患者における皮膚病変およびそう痒の治療 Download PDF

Info

Publication number
JP7410852B2
JP7410852B2 JP2020514620A JP2020514620A JP7410852B2 JP 7410852 B2 JP7410852 B2 JP 7410852B2 JP 2020514620 A JP2020514620 A JP 2020514620A JP 2020514620 A JP2020514620 A JP 2020514620A JP 7410852 B2 JP7410852 B2 JP 7410852B2
Authority
JP
Japan
Prior art keywords
subject
weeks
nemolizumab
pruritus
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020514620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021509103A (ja
Inventor
クリストフ ピケティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2021509103A publication Critical patent/JP2021509103A/ja
Priority to JP2021184447A priority Critical patent/JP7309816B2/ja
Priority to JP2023110385A priority patent/JP7375252B2/ja
Priority to JP2023183030A priority patent/JP7671822B2/ja
Application granted granted Critical
Publication of JP7410852B2 publication Critical patent/JP7410852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020514620A 2019-01-28 2020-01-28 結節性痒疹患者における皮膚病変およびそう痒の治療 Active JP7410852B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021184447A JP7309816B2 (ja) 2019-01-28 2021-11-12 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023110385A JP7375252B2 (ja) 2019-01-28 2023-07-05 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023183030A JP7671822B2 (ja) 2019-01-28 2023-10-25 結節性痒疹患者における皮膚病変およびそう痒の治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797803P 2019-01-28 2019-01-28
US62/797,803 2019-01-28
US201962809404P 2019-02-22 2019-02-22
US62/809,404 2019-02-22
PCT/IB2020/050623 WO2020157636A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021184447A Division JP7309816B2 (ja) 2019-01-28 2021-11-12 結節性痒疹患者における皮膚病変およびそう痒の治療

Publications (2)

Publication Number Publication Date
JP2021509103A JP2021509103A (ja) 2021-03-18
JP7410852B2 true JP7410852B2 (ja) 2024-01-10

Family

ID=69467604

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020514620A Active JP7410852B2 (ja) 2019-01-28 2020-01-28 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2021184447A Active JP7309816B2 (ja) 2019-01-28 2021-11-12 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023110385A Active JP7375252B2 (ja) 2019-01-28 2023-07-05 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023183030A Active JP7671822B2 (ja) 2019-01-28 2023-10-25 結節性痒疹患者における皮膚病変およびそう痒の治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021184447A Active JP7309816B2 (ja) 2019-01-28 2021-11-12 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023110385A Active JP7375252B2 (ja) 2019-01-28 2023-07-05 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023183030A Active JP7671822B2 (ja) 2019-01-28 2023-10-25 結節性痒疹患者における皮膚病変およびそう痒の治療

Country Status (15)

Country Link
US (2) US11236157B2 (https=)
EP (1) EP3917617A1 (https=)
JP (4) JP7410852B2 (https=)
KR (1) KR102953189B1 (https=)
CN (1) CN113660981A (https=)
AU (2) AU2020213978A1 (https=)
BR (1) BR112021014854A2 (https=)
CA (1) CA3127983A1 (https=)
CL (1) CL2021001976A1 (https=)
IL (1) IL285171B2 (https=)
MX (1) MX2021009051A (https=)
PH (1) PH12021551805A1 (https=)
SG (1) SG11202108220YA (https=)
TW (1) TWI861052B (https=)
WO (1) WO2020157636A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021359068A1 (en) * 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
WO2023044313A1 (en) * 2021-09-15 2023-03-23 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
US20240141050A1 (en) * 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
US20120220948A1 (en) 2008-04-18 2012-08-30 Ipsyrng Capital Development, Llc Ergonomic syringe
DE102007056240A1 (de) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh Spritze
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA3199034C (en) 2015-08-24 2025-09-09 Dmk Pharmaceuticals Corporation SYRINGE-TYPE DEVICES
KR101900427B1 (ko) 2018-05-25 2018-09-20 송향숙 가압력 측정이 가능한 주사기용 보조그립

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｇａｌｄｅｒｍａ，ＮＣＴ０３１８１５０３ Ｓａｆｅｔｙ ａｎｄ Ｅｆｆｉｃａｃｙ ｏｆ Ｎｅｍｏｌｉｚｕｍａｂ ｉｎ ＰＮ Ｏｆｆｉｃｉａｌ Ｔｉｔｌｅ： Ａ Ｓｔｕｄｙ ｔｏ Ａｓｓｅｓｓ ｔｈｅ Ｓａｆｅｔｙ ａｎｄ Ｅｆｆｉｃａｃｙ ｏｆ Ｎｅｍｏｌｉｚｕｍａｂ （ＣＤ１４１５２） ｉｎ Ｓｕｂｊｅｃｔｓ Ｗｉｔｈ Ｐｒｕｒｉｇｏ Ｎｏｄｕｌａｒｉｓ （ＰＮ） Ｓｅｃｏｎｄａｒｙ ＩＤｓ，Ｃｌｉｎｉｃａｌ Ｔｒｉａｌｓ，２０１７年 ６月 ７日，Ｒｅｔｒｉｅｖｅｄ ｆｒｏｍ ｔｈｅ Ｉｎｔｅｒｎｅｔ，ＵＲＬ：ｈｔｔｐｓ：／／ｃｌｉｎｉｃａｌｔｒｉａｌｓ．ｇｏｖ／ｃｔ２／ｈｉｓｔｏ，検索日２０２１／０２／１５
ＳＯＮＫＯＬＹ， Ｅｎｉｋｏ ｅｔ ａｌ．，ＩＬ－３１： Ａ ｎｅｗ ｌｉｎｋ ｂｅｔｗｅｅｎ Ｔ ｃｅｌｌｓ ａｎｄ ｐｒｕｒｉｔｕｓ ｉｎ ａｔｏｐｉｃ ｓｋｉｎ ｉｎｆｌａｍａｔｉｏｎ，Ｊｏｕｒｎａｌ ｏｆ Ａｌｌｅｒｇｙ ａｎｄ Ｃｌｉｎｉｃａｌ Ｉｍｍｕｎｏｌｏｇｙ，２００６年，Ｖｏｌ．１１７，Ｎｏ．２，ｐ．４１１－４１７
本田哲也，アトピー性皮膚炎治療の最前線，Ｍｅｂｉｏ，２０１７年１０月，Ｖｏｌ．３４，Ｎｏ．１０，ｐ．１５－２０

Also Published As

Publication number Publication date
PH12021551805A1 (en) 2022-07-18
JP2022028788A (ja) 2022-02-16
JP2023182834A (ja) 2023-12-26
TW202043282A (zh) 2020-12-01
MX2021009051A (es) 2021-12-10
JP2021509103A (ja) 2021-03-18
CA3127983A1 (en) 2020-08-06
JP2023126909A (ja) 2023-09-12
KR102953189B1 (ko) 2026-04-15
US20220177568A1 (en) 2022-06-09
JP7671822B2 (ja) 2025-05-02
CL2021001976A1 (es) 2022-02-11
US20200239563A1 (en) 2020-07-30
IL285171B1 (en) 2025-11-01
TWI861052B (zh) 2024-11-11
AU2020213978A1 (en) 2021-09-23
JP7375252B2 (ja) 2023-11-07
WO2020157636A1 (en) 2020-08-06
US11236157B2 (en) 2022-02-01
CN113660981A (zh) 2021-11-16
KR20210122286A (ko) 2021-10-08
BR112021014854A2 (pt) 2021-12-21
IL285171B2 (en) 2026-03-01
IL285171A (en) 2021-09-30
AU2025263803A1 (en) 2025-11-27
SG11202108220YA (en) 2021-08-30
JP7309816B2 (ja) 2023-07-18
EP3917617A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
JP7375252B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
BR112021008778A2 (pt) Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn
CN112689512B (zh) 用于治疗银屑病的组合物和方法
US20260008859A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
JP2023535792A (ja) コロナウイルス治療のための抗ｃｄ３抗体
TW202120546A (zh) 使用介白素-17（il-17）拮抗劑治療狼瘡性腎炎之方法
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途
CN121889423A (zh) 使用抗gfral抗体治疗恶心和呕吐病症的方法
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
JP2023522907A (ja) 抗ｃｃｌ２４抗体を使用する処置方法
HK40042731A (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40042731B (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200818

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200818

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210714

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211112

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20211208

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230119

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230215

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231222

R150 Certificate of patent or registration of utility model

Ref document number: 7410852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153